The UK’s NICE has approved NHS funding for belantamab mafodotin, a “Trojan horse” infusion targeting multiple myeloma. Around 1,500 patients per year, resistant to standard therapy, will receive treatments every three weeks. The drug penetrates cancer cells and delivers lethal agents directly, tripling progression delay. Patients report remissions within weeks and improved quality of life. This marks a major advancement in blood cancer care within the NHS.
Source: The Times thetimes.co.uk
0 Comments